Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorders

Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorders — Trials · CancerIndex

Clinical trials

Registered studies

13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: Mayo Clinic
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01134341	Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma	completed	Phase 1	34	Acrotech Biopharma Inc.INDUSTRY	2	Dec 18, 2019	clinicaltrials

Data updated 22 days agoSource updated Dec 18, 2019source: clinicaltrials